INT2378

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.59
First Reported 1979
Last Reported 2010
Negated 1
Speculated 1
Reported most in Body
Documents 47
Total Number 48
Disease Relevance 34.55
Pain Relevance 9.90

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (SERPINE1) extracellular region (SERPINE1) plasma membrane (SERPINE1)
Anatomy Link Frequency
platelet 3
plasma 2
extracellular matrix 2
blood 1
fat 1
SERPINE1 (Homo sapiens)
Pain Link Frequency Relevance Heat
Angina 62 100.00 Very High Very High Very High
metalloproteinase 33 100.00 Very High Very High Very High
Inflammatory marker 13 99.80 Very High Very High Very High
Inflammation 205 99.56 Very High Very High Very High
cytokine 49 99.56 Very High Very High Very High
imagery 18 99.36 Very High Very High Very High
fibrosis 97 99.18 Very High Very High Very High
COX2 4 98.96 Very High Very High Very High
Restless leg syndrome 62 98.12 Very High Very High Very High
Osteoarthritis 16 98.12 Very High Very High Very High
Disease Link Frequency Relevance Heat
Cv General 3 Under Development 53 100.00 Very High Very High Very High
Disorder Of Lipid Metabolism 50 100.00 Very High Very High Very High
Intracranial Sinus Thrombosis 24 99.96 Very High Very High Very High
INFLAMMATION 233 99.64 Very High Very High Very High
Hyperinsulinism 14 99.32 Very High Very High Very High
Pulmonary Fibrosis 63 99.18 Very High Very High Very High
Pancreatic Cancer 5 99.16 Very High Very High Very High
Complex Regional Pain Syndromes 6 98.96 Very High Very High Very High
Recurrence 42 98.84 Very High Very High Very High
Coronary Artery Disease 57 98.66 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The plasminogen activator activity of the venous wall was also markedly reduced.
Negative_regulation (reduced) of plasminogen activator
1) Confidence 0.59 Published 1979 Journal S. Afr. Med. J. Section Abstract Doc Link 424966 Disease Relevance 0.69 Pain Relevance 0.09
The authors observed a decrease of platelet aggregation after treatment with indobufen and a decrease of F1 + 2 fragment and PAI-1 antigen after treatment with pentoxifylline.
Negative_regulation (decrease) of PAI-1 in platelet
2) Confidence 0.57 Published 1997 Journal Angiology Section Abstract Doc Link 9071201 Disease Relevance 0.51 Pain Relevance 0.23
We also observed that the prognostic value of PAI-1 is stronger that of uPA.
Negative_regulation (value) of PAI-1
3) Confidence 0.43 Published 2006 Journal BMC Cancer Section Body Doc Link PMC1564186 Disease Relevance 0.98 Pain Relevance 0
Moreover, assessing the PAI-1 mRNA level may also be useful to stratify candidates for the anti-PAI-1 targeted therapies currently being evaluated [37].
Negative_regulation (assessing) of PAI-1 mRNA
4) Confidence 0.43 Published 2006 Journal BMC Cancer Section Body Doc Link PMC1564186 Disease Relevance 0.51 Pain Relevance 0
Specific polymerase chain reaction assays were used to test for cagA and picB in the cagI region, the virD4 homologue in the cagII region, IS605 in the genome and in the cag PAI, the "empty site" indicating absence of the cag PAI, and different vacA gene alleles.
Negative_regulation (absence) of PAI
5) Confidence 0.42 Published 1999 Journal Gastroenterology Section Body Doc Link 10579972 Disease Relevance 0.25 Pain Relevance 0
As shown in Figure 4, the expression levels of PAI-1 and COX-2 measured in the independent STs without CB were found to be very similar to the levels detected in CBs and significantly different from those detected in STs after CB.
Negative_regulation (levels) of PAI-1
6) Confidence 0.41 Published 2006 Journal Breast Cancer Res Section Body Doc Link PMC1779463 Disease Relevance 0.45 Pain Relevance 0.06
Plasminogen activator inhibitor 1 (PAI-1; also known as SERPINE1) was significantly higher expressed (lower ?
Negative_regulation (inhibitor) of Plasminogen activator
7) Confidence 0.41 Published 2006 Journal Breast Cancer Res Section Body Doc Link PMC1779463 Disease Relevance 0 Pain Relevance 0.08
Table 1 lists differences in RNA expression values of PAI-1, COX-2 and ERBB2 for paired samples of each patient.
Negative_regulation (values) of PAI-1
8) Confidence 0.41 Published 2006 Journal Breast Cancer Res Section Body Doc Link PMC1779463 Disease Relevance 0.24 Pain Relevance 0.13
The inhibition of PAI-1 levels by cytokines and reagents which stimulate cartilage resorption (i.e., TNF alpha, interleukin-1 alpha, retinoic acid) and enhancement by cytokines which counter it (i.e., TGF-beta, bFGF) further implicate plasminogen activator in the mechanism(s) of cartilage degradation in diseases such as arthritis.
Negative_regulation (inhibition) of PAI-1 in cartilage associated with disease, arthritis and cytokine
9) Confidence 0.40 Published 1994 Journal Biochim. Biophys. Acta Section Abstract Doc Link 8054359 Disease Relevance 0.56 Pain Relevance 0.43
PAI-1: Plasminogen activator inhibitor-1
Negative_regulation (inhibitor) of PAI-1
10) Confidence 0.40 Published 2004 Journal BMC Neurol Section Body Doc Link PMC539263 Disease Relevance 0.45 Pain Relevance 0.05
After the 1st and the 7th infusion of L-ARG the spontaneous (PAR) as well as the ADP- and collagen-induced platelet aggregation were suppressed, the euglobulin clot lysis time (ECLT) shortened, plasma levels of platelet activator inhibitor (PAI) decreased, and cGMP levels increased.
Negative_regulation (decreased) of PAI in platelet
11) Confidence 0.40 Published 1996 Journal Wien. Klin. Wochenschr. Section Abstract Doc Link 8867484 Disease Relevance 0.30 Pain Relevance 0.08
The effect of therapeutic and pharmacological concentrations of tiaprofenic acid, a non-steroidal anti-inflammatory drug (NSAID), on the synthesis of the plasminogen activators, urokinase plasminogen activator (uPA) and tissue plasminogen activator (tPA), and the plasminogen activator inhibitors 1 and 2 (PAI-1 and PAI-2), by human synovial membranes isolated from osteoarthritis (OA) and rheumatoid arthritis (RA) sufferers was evaluated.
Negative_regulation (inhibitors) of plasminogen activator associated with inflammation, rheumatoid arthritis, cinod and osteoarthritis
12) Confidence 0.37 Published 1992 Journal Br. J. Rheumatol. Section Abstract Doc Link 1555050 Disease Relevance 0.94 Pain Relevance 0.49
The suppressive action of tiaprofenic acid on PAI is not likely to have a significant impact on the balance of plasminogen activators and plasminogen activator inhibitors, as plasminogen activator inhibitors are synthesized in greater amounts than plasminogen activators.
Neg (not) Negative_regulation (inhibitors) of plasminogen activator
13) Confidence 0.37 Published 1992 Journal Br. J. Rheumatol. Section Abstract Doc Link 1555050 Disease Relevance 1.03 Pain Relevance 0.45
The effect of therapeutic and pharmacological concentrations of tiaprofenic acid, a non-steroidal anti-inflammatory drug (NSAID), on the synthesis of the plasminogen activators, urokinase plasminogen activator (uPA) and tissue plasminogen activator (tPA), and the plasminogen activator inhibitors 1 and 2 (PAI-1 and PAI-2), by human synovial membranes isolated from osteoarthritis (OA) and rheumatoid arthritis (RA) sufferers was evaluated.
Negative_regulation (inhibitors) of PAI associated with inflammation, rheumatoid arthritis, cinod and osteoarthritis
14) Confidence 0.37 Published 1992 Journal Br. J. Rheumatol. Section Abstract Doc Link 1555050 Disease Relevance 1.01 Pain Relevance 0.52
The 26 genes that were significantly dysregulated (23 up-regulated and three down-regulated) in the group B samples mainly encoded proteins involved in immune response (interferon pathway, growth factor, growth factor receptor, cytokine: IL8, CXCR4, CCL2, CXCL1, IL6, CCL3, CCL4, LIF) and matrix remodeling (angiogenesis, extracellular matrix, extracellular matrix protease, inhibitors of matrix protease: PAI1, THBS1, PTGS2, HIF1A, MMP9, CTGF, HAS2, PAI2, and MMP2).
Negative_regulation (inhibitors) of PAI1 in extracellular matrix associated with cytokine
15) Confidence 0.37 Published 2008 Journal Hepatology (Baltimore, Md.) Section Body Doc Link PMC2816363 Disease Relevance 0.91 Pain Relevance 0.15
However, patients with lower PAI activity were less likely to have coronary events even when they had diabetes.
Negative_regulation (lower) of PAI
16) Confidence 0.37 Published 2001 Journal Ann. Med. Section Body Doc Link 11370775 Disease Relevance 0.28 Pain Relevance 0
Similar differences, although less pronounced, were observed for cyclooxygenase 2 (COX-2; also known as PTGS2; p < 0.001), urokinase plasminogen activator receptor (uPAR; also known as PLAUR; p = 0.003) and matrix metalloproteinase 1 (MMP1; p = 0.03).
Negative_regulation (receptor) of plasminogen activator associated with metalloproteinase and cox2
17) Confidence 0.35 Published 2006 Journal Breast Cancer Res Section Body Doc Link PMC1779463 Disease Relevance 0.11 Pain Relevance 0.13
PAI-1: Plasminogen activator inhibitor-1
Negative_regulation (inhibitor) of Plasminogen activator
18) Confidence 0.35 Published 2004 Journal BMC Neurol Section Body Doc Link PMC539263 Disease Relevance 0.45 Pain Relevance 0.05
TF and PAI activity decreased to normal ranges after 2 weeks of treatment in the unstable angina group.
Negative_regulation (decreased) of PAI
19) Confidence 0.29 Published 2001 Journal Int. J. Cardiol. Section Body Doc Link 11578720 Disease Relevance 0.06 Pain Relevance 0
However, TrkB and serpin peptidase inhibitor, clade e (nexin, plasminogen activator inhibitor type 1), member 2 (SERPINE2) were present in the set of 1,663 genes and located in module 1.
Negative_regulation (inhibitor) of plasminogen activator inhibitor type 1
20) Confidence 0.28 Published 2008 Journal Genome Biol Section Body Doc Link PMC2760875 Disease Relevance 0.61 Pain Relevance 0.59

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox